ClinicalTrials.gg
TerminatedNCT04404361Updated Jun 5, 2024Results posted

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

A Phase 2 interventional study of Pacritinib and Placebo in COVID19, COVID-19 and COVID, sponsored by CTI BioPharma. Terminated at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-05.

Sponsored by CTI BioPharma (part of Swedish Orphan Biovitrum) · Phase 2, Interventional, and Treatment

Why this study was terminated
decision to close enrollment early

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
480th of 1,321
200 · median 91
Started
2020
with 817 others
Phase 2
349 of 1,859
14 open now
Registered
371st of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 480th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 371st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer.

Read the detailed description

This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer. Severe COVID-19 is defined as confirmed disease in patients who are hospitalized with hypoxia (blood oxygen saturation [SpO2] ≤93% on room air at sea level), respiratory rate >30, arterial oxygen partial pressure [PaO2]/ fraction of inspired oxygen [FiO2] \<300, or lung infiltrates >50% but do not require IMV.

Patients will be randomized 1:1 to receive pacritinib (400 mg once daily [QD] on Day 1, then 200 mg twice daily [BID] from Day 2 to Day 14) + SOC or placebo + SOC.

Assigned treatment will continue for up to Day 14 or until the patient experiences intolerable adverse events (AEs), withdraws consent, or initiates another investigational therapy or until the study is terminated. Assigned therapy may be given for an additional 7 days (for a total of 21 days) with the approval of the Medical Monitor if, in the opinion of the investigator, the patient's clinical signs and symptoms are improving and the potential benefit outweighs the potential risk.In the event of hospital discharge, patients will complete treatment with the assigned therapy as an outpatient.

03

Conditions studied

  • COVID19
  • COVID-19
  • COVID

Browse trials for

Keywords

  • COVID19
  • COVID-19
  • COVID
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hospitalized or will be hospitalized prior to randomization for the treatment of severe COVID-19 with SARS-CoV-2 infection confirmed by either a) a positive reverse transcriptase polymerase chain reaction (RT PCR) or b) an antigen-based test from any respiratory, nasopharyngeal, saliva, blood, or stool specimen at Screening or documented within 1 week prior to the start of Screening (Severe COVID-19 is defined as confirmed disease in patients who are hospitalized with hypoxia [SpO2 ≤93% on room air], respiratory rate >30, PaO2/FiO2 \<300, but do not require IMV).
  2. Age ≥ 18 years
  3. count ≥ 50,000/µL
  4. If fertile, willing to use effective methods during the study
  5. Provision of within 96 hours after hospitalization

Exclusion criteria

Exclusion Criteria:

  1. In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments
  2. Currently intubated or intubated between screening and randomization
  3. Suspected active uncontrolled bacterial, fungal, viral, or other infection (besides COVID 19)
  4. Prior allogenic hematopoietic stem cell transplantation
  5. Active lung cancer or history of lung cancer within the past 12 months
  6. Any active grade 2 or higher hemorrhage
  7. Any active gastrointestinal or metabolic condition that could interfere with absorption of oral medication
  8. Uncontrolled intercurrent illness that, in the judgment of the treating physician, would limit compliance with study requirements
  9. Known seropositivity for with cluster of differentiation 4 (CD4) count \< 200/mm3 within 3 months prior to randomization
  10. Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination
  11. Concurrent enrollment in another interventional trial ( COVID-19 antiviral studies are permitted)
  12. Serum creatinine > 2.5 mg/dL
  13. Total > 4× the
  14. corrected by the Fridericia method (QTcF) prolongation > 480 msec
  15. Known history of Class II, III, or IV congestive heart failure prior to hospital admission
  16. Known allergic reaction to any Janus kinase 2 (JAK2) inhibitor
  17. Exposure to any JAK2 inhibitor within 28 days
  18. Currently receiving a strong inhibitor or strong P450 inducer (Appendix 1 and Appendix 2, respectively) and unable to stop the medication prior to the first dose of study drug and throughout the duration of study drug administration
  19. Treatment with cytoreductive chemotherapy administered within 14 days prior to randomization
  20. Administration of an IL 1 or IL 6 blocking immunomodulatory agent (such as tocilizumab, canakinumab, sarilumab, anakinra) within 48 hours prior to randomization
  21. Currently receiving therapeutic anticoagulation or anti medication and unable to stop the medication prior to randomization. Prophylactic anticoagulation therapy or aspirin (≤ 100mg) are permitted.
  22. Unable to ingest capsules or tablets at randomization
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Pacritinib and SOC

    Pacritinib 400 mg once daily \[QD\] on Day 1, then 200 mg twice daily \[BID\] from Day 2 to Day 14) + SOC

    Drug: Pacritinib

  • Placebo comparator
    Placebo and SOC

    4 capsules once daily \[QD\] on Day 1, then 2 capsules twice daily \[BID\] from Day 2 to Day 14) + SOC

    Drug: Placebo

Interventions

  • 100 mg capsules

    Also known as: SB1518, Oral Jak Inhibitor, Oral Irak inhibitor, Oral Csf1 inhibitor

  • DrugPlacebo

    Placebo capsules matching pacritinib 100 mg capsules

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Progression to IMV and/or ECMO or Death

    The percentage is calculated as the number of patients who progress to IMV/ECMO or death divided by the total number of patients in the ITT population (n/N \* 100).

    Time frame: Baseline to Day 28

Secondary outcomes

  1. The Number of Ventilator-Free Days

    the number of days that patients are alive and not intubated, from randomization to Day 28

    Time frame: Baseline to Day 28

  2. The Mortality Rate at Day 28

    the number of patients with outcome of death during the 28 days following randomization

    Time frame: Baseline to Day 28

  3. The Mortality Rate at Day 15

    the number of patients with outcome of death in the 15 days following randomization

    Time frame: Baseline to Day 15

  4. The Time to Improvement by at Least 2 Points Relative to Baseline on the 7-point Ordinal Scale of Clinical Status

    Time to Improvement (days) = Date of improvement - Date of randomization + 1. Date of Improvement was defined as the time to first ordinal scale assessment 2 points or more lower than the baseline clinical status assessment.

    Time frame: Baseline, Day 8, 15, 22, and 28.

  5. The Clinical Status as Assessed by the 7-point Ordinal Scale of Clinical Status at Days 8, 15, 22, and 28

    Clinical status assessment based on the adapted scale from Cao et al. The patient CS is summarized by study visit. STATUS: 1. not hospitalized with resumption of normal activities; 2. not hospitalized but unable to resume normal activities; 3. hospitalization, not requiring supplemental oxygen; 4. hospitalization, requiring supplemental oxygen not meeting the criteria for categories 5 or 6; 5. hospitalization, on non-invasive positive pressure ventilation or high-flow nasal cannula; 6. hospitalization, requiring IMV and/or ECMO; 7. death.

    Time frame: Baseline, Day 8, 15, 22, 28

  6. The Rate of Use of Immunomodulatory Agents as Treatment for COVID-19

    the proportion of patients reporting use of medications such as corticosteroids, tocilizumab, anakinra, or eculizumab as treatment for COVID-19, during 28 days following randomization

    Time frame: Baseline to Day 28

07

Results

Posted Jun 5, 2024

Participant flow

Participant flow — Overall Study
MilestonePacritinib and SOCPlacebo and SOC
Started99101
Completed6880
Not completed3121
Withdrew: Death1212
Withdrew: Withdrawal by subject135
Withdrew: Lost to follow-up63
Withdrew: Patient hospitalized and was nonverbal at the end of the study01

Outcome measures

PrimaryPercentage of Participants With Progression to IMV and/or ECMO or Death

The percentage is calculated as the number of patients who progress to IMV/ECMO or death divided by the total number of patients in the ITT population (n/N \* 100).

Time frame:
Baseline to Day 28
Reported as:
Count of participants · Participants
Percentage of Participants With Progression to IMV and/or ECMO or Death
ParticipantsPacritinib and SOCPlacebo and SOC
Percentage of Participants With Progression to IMV and/or ECMO or Death2625
Statistical analysis
  • Pacritinib and SOC vs Placebo and SOC · Cochran-Mantel-Haenszel · p = 0.8516 · Risk difference (rd): 1.51 · 95% CI -10.55 to 13.53Cochran-Mantel-Haenszel test stratified by age (\<60 years versus ≥60 years) and 7-point clinical status scale (baseline 3 or 4 versus 5).
SecondaryThe Number of Ventilator-Free Days

the number of days that patients are alive and not intubated, from randomization to Day 28

Time frame:
Baseline to Day 28
Reported as:
Mean · days
The Number of Ventilator-Free Days
daysPacritinib and SOCPlacebo and SOC
The Number of Ventilator-Free Days22.1 ± 10.222.6 ± 9.35
Statistical analysis
  • Pacritinib and SOC vs Placebo and SOC · Wilcoxon (Mann-Whitney) · p = 0.7494
SecondaryThe Mortality Rate at Day 28

the number of patients with outcome of death during the 28 days following randomization

Time frame:
Baseline to Day 28
Reported as:
Number · % of patients with outcome of death /D28
The Mortality Rate at Day 28
% of patients with outcome of death /D28Pacritinib and SOCPlacebo and SOC
The Mortality Rate at Day 2810.1 (5.0 to 17.8)7.9 (3.5 to 15.0)
Statistical analysis
  • Pacritinib and SOC vs Placebo and SOC · Cochran-Mantel-Haenszel · p = 0.6323 · Odds ratio (or): 1.29 · 95% CI 0.46 to 3.58OR from a CMH test stratified by randomization stratification factors age (\<60 years versus ≥60 years) and 7-point clinical status scale (baseline 3 or 4 versus 5) as entered in the IXRS
SecondaryThe Mortality Rate at Day 15

the number of patients with outcome of death in the 15 days following randomization

Time frame:
Baseline to Day 15
Reported as:
Number · % of patients with outcome of death /D15
The Mortality Rate at Day 15
% of patients with outcome of death /D15Pacritinib and SOCPlacebo and SOC
The Mortality Rate at Day 155.1 (1.7 to 11.4)4.0 (1.1 to 9.8)
Statistical analysis
  • Pacritinib and SOC vs Placebo and SOC · Cochran-Mantel-Haenszel · p = 0.7541 · Odds ratio (or): 1.25 · 95% CI 0.31 to 4.96OR from a CMH test Stratified by randomization stratification factors age (\<60 years versus ≥60 years) and 7-point clinical status scale (baseline 3 or 4 versus 5) as entered in the IXRS
SecondaryThe Time to Improvement by at Least 2 Points Relative to Baseline on the 7-point Ordinal Scale of Clinical Status

Time to Improvement (days) = Date of improvement - Date of randomization + 1. Date of Improvement was defined as the time to first ordinal scale assessment 2 points or more lower than the baseline clinical status assessment.

Time frame:
Baseline, Day 8, 15, 22, and 28.
Reported as:
Median · days
The Time to Improvement by at Least 2 Points Relative to Baseline on the 7-point Ordinal Scale of Clinical Status
daysPacritinib and SOCPlacebo and SOC
The Time to Improvement by at Least 2 Points Relative to Baseline on the 7-point Ordinal Scale of Clinical Status9.0 (8.0 to 10.0)9.0 (7.0 to 11.0)
Statistical analysis
  • Pacritinib and SOC vs Placebo and SOC · Log Rank · p = 0.5666 (log-rank test stratified by randomization stratification factors age (\<60 years versus ≥60 years) and 7-point clinical status scale (baseline 3 or 4 versus 5) as entered in the IXRS) · Hazard ratio (hr): 1.09 · 95% CI 0.79 to 1.53estimated using a stratified Cox proportional hazards model stratified by randomization stratification factors age (\<60 years versus ≥60 years) and 7-point clinical status scale (baseline 3 or 4 versus 5)
SecondaryThe Clinical Status as Assessed by the 7-point Ordinal Scale of Clinical Status at Days 8, 15, 22, and 28

Clinical status assessment based on the adapted scale from Cao et al. The patient CS is summarized by study visit. STATUS: 1. not hospitalized with resumption of normal activities; 2. not hospitalized but unable to resume normal activities; 3. hospitalization, not requiring supplemental oxygen; 4. hospitalization, requiring supplemental oxygen not meeting the criteria for categories 5 or 6; 5. hospitalization, on non-invasive positive pressure ventilation or high-flow nasal cannula; 6. hospitalization, requiring IMV and/or ECMO; 7. death.

Time frame:
Baseline, Day 8, 15, 22, 28
Reported as:
Number · participants
The Clinical Status as Assessed by the 7-point Ordinal Scale of Clinical Status at Days 8, 15, 22, and 28
participantsPacritinib and SOCPlacebo and SOC
Day 8 : Clinical status 11511
Day 8 : Clinical status 22337
Day 8 : Clinical status 353
Day 8 : Clinical status 42011
Day 8 : Clinical status 51520
Day 8 : Clinical status 6914
Day 8 : Clinical status 701
Day 8 : Clinical status Missing124
Day 15: Clinical status 11917
Day 15: Clinical status 24347
Day 15: Clinical status 311
Day 15: Clinical status 428
Day 15: Clinical status 552
Day 15: Clinical status 61016
Day 15: Clinical status 702
Day 15: Clinical status Missing198
Day 22: Clinical status 12724
Day 22: Clinical status 23648
Day 22: Clinical status 310
Day 22: Clinical status 401
Day 22: Clinical status 541
Day 22: Clinical status 6712
Day 22: Clinical status 731
Day 22: Clinical status Missing2114
Day 28: Clinical status 13130
Day 28: Clinical status 23242
Day 28: Clinical status 300
Day 28: Clinical status 432
Day 28: Clinical status 521
Day 28: Clinical status 6610
Day 28: Clinical status 701
Day 28: Clinical status Missing2515
SecondaryThe Rate of Use of Immunomodulatory Agents as Treatment for COVID-19

the proportion of patients reporting use of medications such as corticosteroids, tocilizumab, anakinra, or eculizumab as treatment for COVID-19, during 28 days following randomization

Time frame:
Baseline to Day 28
Reported as:
Count of participants · Participants
The Rate of Use of Immunomodulatory Agents as Treatment for COVID-19
ParticipantsPacritinib and SOCPlacebo and SOC
The Rate of Use of Immunomodulatory Agents as Treatment for COVID-199796
Statistical analysis
  • Pacritinib and SOC vs Placebo and SOC · Chi-squared · p = 0.2722 · Odds ratio (or): 2.46 · 95% CI 0.47 to 12.93

Adverse events

Collected over Daily (Days 2 through 28), End of Treatment (for inpatients only), Day of hospital discharge, Weekly outpatient assessment (to evaluate daily AEs), 30-day Post End of Treatment. AE data were collected from the time of randomization through 30 days following the last dose of pacritinib/placebo.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pacritinib and SOC12/96 (12.5%)20/96 (20.8%)74/96 (77.1%)
Placebo and SOC12/101 (11.9%)33/101 (32.7%)79/101 (78.2%)
Most frequent serious events
Most frequent serious events
EventPacritinib and SOCPlacebo and SOC
respiratory failureRespiratory, thoracic and mediastinal disorders7/9615/101
acute respiratory failureRespiratory, thoracic and mediastinal disorders6/968/101
hypoxiaRespiratory, thoracic and mediastinal disorders4/966/101
septic shockInfections and infestations2/966/101
acute kidney injuryRenal and urinary disorders3/963/101
acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders3/960/101
cardiac arrestCardiac disorders1/963/101
pulmonary embolismRespiratory, thoracic and mediastinal disorders0/963/101
hypotensionCardiac disorders2/961/101
cardio-respiratory arrestCardiac disorders2/960/101
Most frequent other events
Showing 10 of 23
Most frequent other events
EventPacritinib and SOCPlacebo and SOC
anaemiaBlood and lymphatic system disorders12/9618/101
Alanine aminotransferase increasedHepatobiliary disorders15/9617/101
bradycardiaCardiac disorders15/9611/101
constipationGastrointestinal disorders12/9613/101
hypokalaemiaMetabolism and nutrition disorders12/9612/101
diarrhoeaGastrointestinal disorders12/964/101
hyperkalaemiaMetabolism and nutrition disorders9/9611/101
hyperglycaemiaMetabolism and nutrition disorders3/9611/101
acute kidney injuryRenal and urinary disorders9/967/101
Aspartate aminotransferase increasedHepatobiliary disorders9/966/101

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pacritinib and SOCPlacebo and SOCTotal
Median60.0 (19 to 87)59.0 (28 to 94)60.0 (19 to 94)
Age, Customized
Age, Customized(Participants)Pacritinib and SOCPlacebo and SOCTotal
Age group — <60 years485199
Age group — ≥60 years5150101
Sex: Female, Male
Sex: Female, Male(Participants)Pacritinib and SOCPlacebo and SOCTotal
Female433780
Male5664120
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pacritinib and SOCPlacebo and SOCTotal
Hispanic or Latino131427
Not Hispanic or Latino7981160
Unknown or Not Reported7613
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pacritinib and SOCPlacebo and SOCTotal
American Indian or Alaska Native022
Asian224
Native Hawaiian or Other Pacific Islander101
Black or African American171936
White7472146
More than one race000
Unknown or Not Reported5611
Region of Enrollment
Region of Enrollment(participants)Pacritinib and SOCPlacebo and SOCTotal
United States99101200
08

Study locations

21 sites
  • St. Jude Hospital Yorba Linda dba St. Joseph Heritage Healthcare
    Orange, California 92868, United States
  • Ascension St. Vincent's Riverside Hospital
    Jacksonville, Florida 32204, United States
  • Grady Memorial Hospital
    Atlanta, Georgia 30303, United States
  • St. Vincent Medical Group, Inc
    Indianapolis, Indiana 46220, United States
  • St. Agnes Healthcare
    Baltimore, Maryland 21229, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Ascension St. John Hospital
    Detroit, Michigan 48236, United States
  • Ascension Providence Hospital - Novi Campus
    Novi, Michigan 48374, United States
  • Providence Cancer Institute
    Southfield, Michigan 48075, United States
  • Atlantic Melanoma Center
    Morristown, New Jersey 07960, United States
  • Overlook Medical Center
    Morristown, New Jersey 07960, United States
  • Chilton Medical Center
    Pompton Plains, New Jersey 07444, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • St. John Medical Center
    Tulsa, Oklahoma 74104, United States
  • Albert Einstein Medical Center
    Philadelphia, Pennsylvania 19141, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • The Miriam Hospital
    Providence, Rhode Island 02903, United States
  • Ascension St. Francis Hospital
    Milwaukee, Wisconsin 53215, United States
  • Ascension All Saints
    Racine, Wisconsin 53405, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Sep 2021, 15 months.

Results were first posted in Jun 2024, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2020
First posted
May 27, 2020
StartActual
May 22, 2020
Primary completionActual
Sep 21, 2021
CompletionActual
Sep 21, 2021
Results first posted
Jun 5, 2024
Last update
Jun 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04404361
Lead sponsor
CTI BioPharma
Responsible party
Sponsor
First posted
May 27, 2020
Start date
May 22, 2020
Primary completion
Sep 21, 2021
Completion
Sep 21, 2021
Results posted
Jun 5, 2024
Last update
Jun 5, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pacritinib

Start the discussion